Meeting ReportOncology, Basic and Translational - Early Phase (Phase 0 or I) human studies
[68Ga]Ga-RYZ-GPC3; a glypican-3 targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging. A future game-changer in HCC?
Arthur Braat, Alex Poot, Constantin Lapa, Marnix Lam, Matthias Eiber, Wolfgang Weber, Ye Yuan, Jessica Rearden, Ken Song and Ralph Bundschuh
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241739;
Arthur Braat
1UMC Utrecht
Alex Poot
2University Medical Center Utrecht
Constantin Lapa
3University of Augsburg
Marnix Lam
Matthias Eiber
4Technical University Munich
Wolfgang Weber
5Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine
Ye Yuan
6RayzeBio
Jessica Rearden
7RayzeBio, San Diego, CA
Ken Song
7RayzeBio, San Diego, CA
Ralph Bundschuh
8Nuclear Medicine, Faculty of Medicine, University Hospital Augsburg, Augsburg, Germany

Article Figures & Data
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
[68Ga]Ga-RYZ-GPC3; a glypican-3 targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging. A future game-changer in HCC?
Arthur Braat, Alex Poot, Constantin Lapa, Marnix Lam, Matthias Eiber, Wolfgang Weber, Ye Yuan, Jessica Rearden, Ken Song, Ralph Bundschuh
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241739;
[68Ga]Ga-RYZ-GPC3; a glypican-3 targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular imaging. A future game-changer in HCC?
Arthur Braat, Alex Poot, Constantin Lapa, Marnix Lam, Matthias Eiber, Wolfgang Weber, Ye Yuan, Jessica Rearden, Ken Song, Ralph Bundschuh
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241739;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.